(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -11.71%412.62B | -10.65%298.84B | 3.81%149.95B | 6.95%633.87B | 17.70%467.32B | 15.65%334.46B | 22.39%144.45B | 18.40%592.67B | 13.61%397.04B | 15.22%289.2B |
Operating income | -11.71%412.62B | -10.65%298.84B | 3.81%149.95B | 6.95%633.87B | 17.70%467.32B | 15.65%334.46B | 22.39%144.45B | 18.40%592.67B | 13.61%397.04B | 15.22%289.2B |
Operating expenses | 11.53%-375.3B | 10.44%-271.8B | -5.25%-137.67B | -6.90%-572.46B | -18.21%-424.22B | -15.74%-303.47B | -23.84%-130.81B | -19.69%-535.52B | -14.04%-358.87B | -15.73%-262.19B |
Gross profit | -13.43%37.32B | -12.74%27.04B | -10.04%12.27B | 7.46%61.41B | 12.92%43.11B | 14.72%30.99B | 10.05%13.64B | 7.56%57.15B | 9.66%38.18B | 10.49%27.01B |
Selling expenses | -0.42%-2.02B | 0.43%-1.39B | -6.35%-699.61M | -9.93%-3.17B | -14.71%-2.01B | -13.42%-1.39B | -10.80%-657.85M | -5.12%-2.88B | -0.16%-1.76B | -6.19%-1.23B |
Administrative expenses | -1.85%-8.23B | -5.21%-5.71B | -3.76%-3.19B | -9.64%-12.36B | -10.94%-8.08B | -9.83%-5.43B | -10.56%-3.07B | -3.22%-11.27B | -0.40%-7.29B | 2.02%-4.94B |
Research and development expenses | 12.09%-11.9B | 11.25%-8.07B | -0.11%-2.82B | -5.33%-19.73B | -15.76%-13.54B | -18.99%-9.09B | -7.14%-2.81B | -17.81%-18.73B | -17.88%-11.69B | -27.13%-7.64B |
Profit from asset sales | 1,856.49%1B | 2,395.55%847.46M | 832.47%147.71M | 118.58%663.08M | -77.69%51.26M | -67.28%33.96M | 117.27%15.84M | -55.99%303.36M | -47.48%229.74M | -75.74%103.78M |
Revaluation surplus | 83.85%-74.08M | 34.04%-216.6M | -5,553.63%-183.86M | 1.12%-314.22M | -10.35%-458.64M | -151.26%-328.38M | -140.28%-3.25M | -278.59%-317.78M | -604.71%-415.61M | -353.88%-130.7M |
-Changes in the fair value of other assets | 83.85%-74.08M | 34.04%-216.6M | -5,553.63%-183.86M | 1.12%-314.22M | -10.35%-458.64M | -151.26%-328.38M | -140.28%-3.25M | -278.59%-317.78M | -604.71%-415.61M | -353.88%-130.7M |
Impairment and provision | -7.05%-4.3B | -57.88%-4.87B | -0.46%-915.76M | -80.37%-8.95B | -0.78%-4.01B | -5.58%-3.08B | -7.47%-911.58M | 7.07%-4.96B | -25.11%-3.98B | -38.32%-2.92B |
-Other impairment is provision | -7.05%-4.3B | -57.88%-4.87B | -0.46%-915.76M | -80.37%-8.95B | -0.78%-4.01B | -5.58%-3.08B | -7.47%-911.58M | 7.07%-4.96B | -25.11%-3.98B | -38.32%-2.92B |
Special items of operating profit | 24.12%-389.18M | 30.58%-351.75M | 37.38%-150.35M | 14.93%-927.25M | 44.19%-512.87M | 19.45%-506.66M | -85.71%-240.12M | 20.17%-1.09B | -673.91%-919.01M | -18.17%-628.99M |
Operating profit | -24.63%9.93B | -37.45%6.38B | -25.39%4.1B | -9.93%14.7B | 21.42%13.17B | 17.01%10.2B | 8.29%5.49B | 7.28%16.33B | -7.00%10.85B | -2.56%8.72B |
Financing cost | -94.83%-1.01B | -156.36%-637.3M | -16.02%-222.82M | -5.13%-989.12M | -1,280.18%-516.54M | -127.33%-248.6M | 36.71%-192.05M | 10.83%-940.84M | 103.55%43.77M | 89.69%-109.36M |
Special items of earning before tax | -116.22%-4.72M | -12.95%-63.46M | -55.61%13.14M | 576.18%48.94M | 24.10%29.08M | -249.57%-56.18M | 24.14%29.6M | 104.81%7.24M | -85.00%23.44M | -73.48%37.56M |
Earning before tax | -29.71%8.92B | -42.61%5.68B | -27.05%3.89B | -10.57%13.76B | 16.21%12.69B | 14.46%9.9B | 11.22%5.33B | 9.85%15.39B | 3.09%10.92B | 7.69%8.65B |
Tax | 44.30%-1.22B | 19.60%-980.52M | 21.02%-743.95M | 4.14%-2.36B | -10.81%-2.19B | 5.60%-1.22B | 5.76%-941.91M | -2.31%-2.46B | 4.18%-1.97B | 10.28%-1.29B |
After-tax profit from continuing operations | -26.67%7.7B | -45.84%4.7B | -28.34%3.14B | -11.80%11.41B | 17.40%10.5B | 17.98%8.68B | 15.69%4.39B | 11.41%12.93B | 4.85%8.94B | 11.62%7.36B |
Earning after tax | -26.67%7.7B | -45.84%4.7B | -28.34%3.14B | -11.80%11.41B | 17.40%10.5B | 17.98%8.68B | 15.69%4.39B | 11.41%12.93B | 4.85%8.94B | 11.62%7.36B |
Minority profit | -62.49%868.48M | -62.30%550.89M | -54.16%466.2M | 3.02%2.74B | 3.74%2.32B | -1.50%1.46B | -8.58%1.02B | -17.84%2.66B | -7.07%2.23B | -10.27%1.48B |
Profit attributable to shareholders | -16.53%6.83B | -42.50%4.15B | -20.56%2.68B | -15.63%8.67B | 21.94%8.18B | 22.90%7.22B | 25.77%3.37B | 22.70%10.28B | 9.52%6.71B | 18.95%5.87B |
Basic earnings per share | -22.58%0.24 | -57.69%0.11 | -20.00%0.12 | -26.67%0.33 | 10.71%0.31 | 8.33%0.26 | 25.00%0.15 | 28.57%0.45 | 7.69%0.28 | 14.29%0.24 |
Diluted earnings per share | -22.58%0.24 | -57.69%0.11 | -20.00%0.12 | -26.67%0.33 | 10.71%0.31 | 8.33%0.26 | 25.00%0.15 | 28.57%0.45 | 0.28 | 14.29%0.24 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data